广济药业(000952) - 2022 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 178,873,451.83, representing a 1.45% increase compared to CNY 176,325,538.59 in the same period last year[4] - Net profit attributable to shareholders decreased by 39.62% to CNY 8,356,171.56 from CNY 13,838,265.84 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 178,873,451.83, a slight increase from CNY 176,325,538.59 in Q1 2021, representing a growth of approximately 1.4%[22] - Net profit for Q1 2022 was CNY 7,655,581.24, down from CNY 12,935,440.72 in Q1 2021, reflecting a decrease of approximately 40.5%[24] - The company's operating profit for Q1 2022 was CNY 8,728,468.35, compared to CNY 17,897,295.19 in the same period last year, a decline of about 51.2%[23] - The company reported a total comprehensive income of CNY 7,647,988.93 for Q1 2022, down from CNY 12,935,440.72 in Q1 2021, reflecting a decrease of approximately 40.5%[24] Cash Flow and Financial Position - The net cash flow from operating activities was negative at CNY -329,051.98, a decline of 101.15% compared to CNY 28,496,950.04 in the previous year[10] - Cash flow from operating activities in Q1 2022 was CNY -329,051.98, a significant decline compared to CNY 28,496,950.04 in Q1 2021[26] - The net cash flow from investment activities was -46,697,286.75, compared to -23,944,091.49 in the previous year, indicating a significant increase in cash outflow for investments[27] - Cash inflow from financing activities totaled 334,443,480.00, up from 102,651,520.00 in the same period last year, reflecting a strong increase in financing efforts[27] - The net cash flow from financing activities was 162,240,812.11, compared to -28,468,667.35 in the previous year, showing a positive turnaround in financing[27] - The total cash and cash equivalents at the end of the period reached 318,188,097.11, an increase from 265,723,641.72 in the previous year[27] - The company received cash from borrowings amounting to 275,000,000.00, significantly higher than 102,651,520.00 in the previous year, indicating increased leverage[27] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was 46,998,496.47, compared to 24,183,491.49 in the previous year, reflecting increased capital expenditures[27] - The cash paid for debt repayment was 167,250,000.00, compared to 126,316,855.83 in the previous year, indicating a higher focus on debt management[27] Assets and Liabilities - Total assets increased by 13.06% to CNY 2,316,525,859.76 from CNY 2,048,896,426.54 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were RMB 1,200,000,000, reflecting an increase from the previous year[19] - Total liabilities as of Q1 2022 were CNY 858,073,922.87, compared to CNY 598,092,478.58 in the previous year, indicating an increase of approximately 43.5%[23] - The company's long-term borrowings rose dramatically by 521.04% to CNY 213,950,000.00, reflecting increased financing needs for operations[8] - The company’s short-term borrowings increased to RMB 255,000,000 from RMB 236,279,188.89, showing a rise of approximately 7.3%[19] Inventory and Receivables - The company’s inventory increased by 32.49% to CNY 218,384,674.56, attributed to higher procurement of pharmaceutical distribution and trading goods[8] - Accounts receivable rose to RMB 193,938,139.72 from RMB 182,981,957.15, indicating an increase of approximately 6.4%[18] - The company reported a significant increase in other receivables, which rose to RMB 13,739,352.64 from RMB 9,764,746.75, indicating an increase of about 40.3%[18] Government Support and Incentives - The company received government subsidies amounting to CNY 6,383,687.72, which is a 96.98% increase compared to the previous year[10] - A total of 8.649 million restricted stock units were granted to 118 eligible participants at a price of RMB 3.52 per share as part of the incentive plan approved by the Hubei Provincial Government[14] Research and Development - The company plans to implement a mixed reform strategy by introducing a research and development team to enhance its capabilities in drug formulation and production[16] - The company established a subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its R&D capabilities and product development platform[16] - Research and development expenses for Q1 2022 amounted to CNY 9,185,119.75, an increase from CNY 7,506,265.22 in the previous year, representing a growth of about 22.4%[23] Miscellaneous - The impact of exchange rate changes on cash and cash equivalents was -98,645.94, contrasting with a positive impact of 101,256.70 in the previous year[27] - The first quarter report was not audited, which may affect the reliability of the financial data presented[28]